Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

CORZ

Core Scientific Inc

May 09 • 04:00PM ET

3.90

Dollar change +0.42
Percentage change 12.07	%

Technology • Software - Infrastructure • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI BLOK BITQ WGMI FDIG IBLC SATO BLKC TXSS BWEB

Index	-	P/E	27.94	EPS (ttm)	0.14	Insider Own	11.33%	Shs Outstand	386.88M	Perf Week	21.88%
Market Cap	693.34M	Forward P/E	14.57	EPS next Y	0.27	Insider Trans	1.98%	Shs Float	157.63M	Perf Month	24.60%
Income	-35.41M	PEG	-	EPS next Q	-0.02	Inst Own	7.27%	Short Float	4.71%	Perf Quarter	8.33%
Sales	561.04M	P/S	1.24	EPS this Y	123.88%	Inst Trans	-	Short Ratio	2.31	Perf Half Y	-
Book/sh	-1.75	P/B	-	EPS next Y	72.48%	ROA	-4.50%	Short Interest	7.43M	Perf Year	-
Cash/sh	0.64	P/C	6.07	EPS next 5Y	-	ROE	-7418.13%	52W Range	2.61 - 6.10	Perf YTD	13.37%
Dividend Est.	-	P/FCF	14.16	EPS past 5Y	-	ROI	-11.49%	52W High	-36.07%	Beta	-
Dividend TTM	-	Quick Ratio	0.20	Sales past 5Y	-1.31%	Gross Margin	30.18%	52W Low	49.43%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	1.04	EPS Y/Y TTM	105.53%	Oper. Margin	12.21%	RSI (14)	64.97	Volatility	6.56% 7.51%
Employees	286	Debt/Eq	-	Sales Y/Y TTM	-1.30%	Profit Margin	-6.31%	Recom	1.67	Target Price	6.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	2608.04%	Payout	-	Rel Volume	3.37	Prev Close	3.48
Sales Surprise	20.74%	EPS Surprise	630.34%	Sales Q/Q	48.60%	Earnings	May 08 AMC	Avg Volume	3.21M	Price	3.90
SMA20	23.20%	SMA50	15.90%	SMA200	15.54%	Trades		Volume	10,823,656	Change	12.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-24	Upgrade	Compass Point	Neutral → Buy	$1 → $8.50
Jan-25-24	Upgrade	H.C. Wainwright	Neutral → Buy	$5

Today 03:51AM	Core Scientific Inc (CORZ) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ... (GuruFocus.com) +12.07%
May-08-24 04:10PM	Core Scientific Announces Fiscal First Quarter 2024 Results (Business Wire)
May-06-24 09:10AM	Core Scientific Announces April 2024 Production and Operations Updates (Business Wire)
May-03-24 04:07PM	Trinity Capital Inc. (NASDAQ:TRIN) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:10AM	Core Scientific, Inc. Schedules First Quarter Fiscal Year 2024 Earnings Release, Conference Call and Webcast (Business Wire)
04:36PM	Loading…
Apr-17-24 04:36PM	Bitcoins Halving Is Coming. Miners Are Looking for New Ways to Make Money. (The Wall Street Journal)
Apr-16-24 09:10AM	Core Scientific to Expand its Denton, Texas Bitcoin Mining Data Center by 72 Megawatts (Business Wire)
Apr-15-24 09:10AM	Core Scientific Files Registration Statement for Shares Held by Existing Shareholders (Business Wire) -5.98%
Apr-05-24 09:10AM	Core Scientific Announces March 2024 Production and Operations Updates (Business Wire)
Mar-19-24 01:26AM	Director Yadin Rozov Acquires 80,000 Shares of Core Scientific Inc (CORZ) (GuruFocus.com)
01:26AM	Core Scientific Inc (CORZ) CEO Adam Sullivan Acquires 65,300 Shares (GuruFocus.com)
Mar-12-24 04:10PM	Core Scientific Announces Fiscal Fourth Quarter and Full Fiscal Year 2023 Results (Business Wire)
Mar-07-24 12:02PM	Trinity Capital Inc. (NASDAQ:TRIN) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.21%
Mar-06-24 04:10PM	Core Scientific to Provide CoreWeave up to 16 MW of Data Center Infrastructure to Support AI and HPC Workloads in Long Term Hosting Contract with Potential Revenue of More than $100 Million (Business Wire) +5.49%
07:05AM	Trinity Capital Inc. Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
04:30PM	Loading…
Mar-05-24 04:30PM	Core Scientific, Inc. Schedules Full Fiscal Year 2023 Earnings Release, Conference Call and Webcast (Business Wire) -9.00%
04:19PM	Core Scientific Announces February 2024 Production and Operations Updates (Business Wire)
Feb-05-24 09:10AM	Core Scientific Announces January 2024 Production and Operations Updates (Business Wire) +5.37%

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Becker Todd A	Director	Mar 15 '24	Buy	3.16	130,000	410,163	134,250	Mar 19 04:17 PM
Patten Jarrod M	Director	Mar 15 '24	Buy	3.32	100,000	332,220	100,000	Mar 19 04:17 PM
Rozov Yadin	Director	Mar 15 '24	Buy	3.07	80,000	245,968	80,000	Mar 18 07:45 PM
Sullivan Adam Taylor	Chief Executive Officer	Mar 15 '24	Buy	3.06	65,300	199,962	93,753	Mar 18 07:46 PM
Weiss Eric Stanton	Director	Mar 15 '24	Buy	3.03	15,000	45,396	15,000	Mar 18 07:46 PM

Open in Screener

DAVE

Dave Inc

May 09 • 04:00PM ET

53.09

Dollar change +2.31
Percentage change 4.55	%

Technology • Software - Application • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: DWAS VTI VXF IWC AVSC DFAC DCOR

Index	-	P/E	-	EPS (ttm)	-0.30	Insider Own	26.59%	Shs Outstand	10.63M	Perf Week	20.99%
Market Cap	657.25M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-6.62%	Shs Float	9.09M	Perf Month	46.33%
Income	-0.23M	PEG	-	EPS next Q	-0.24	Inst Own	10.87%	Short Float	7.56%	Perf Quarter	164.00%
Sales	273.88M	P/S	2.40	EPS this Y	151.11%	Inst Trans	-63.25%	Short Ratio	5.37	Perf Half Y	802.89%
Book/sh	10.32	P/B	5.14	EPS next Y	-110.58%	ROA	-0.08%	Short Interest	0.69M	Perf Year	1001.45%
Cash/sh	8.05	P/C	6.59	EPS next 5Y	-	ROE	-0.20%	52W Range	4.47 - 63.50	Perf YTD	533.15%
Dividend Est.	-	P/FCF	11.22	EPS past 5Y	-	ROI	-0.11%	52W High	-16.39%	Beta	3.02
Dividend TTM	-	Quick Ratio	7.47	Sales past 5Y	30.18%	Gross Margin	54.51%	52W Low	1088.55%	ATR (14)	4.67
Dividend Ex-Date	-	Current Ratio	7.47	EPS Y/Y TTM	99.02%	Oper. Margin	-8.83%	RSI (14)	71.05	Volatility	12.01% 10.02%
Employees	285	Debt/Eq	0.60	Sales Y/Y TTM	23.85%	Profit Margin	-0.08%	Recom	1.00	Target Price	70.00
Option/Short	Yes / Yes	LT Debt/Eq	0.59	EPS Q/Q	318.84%	Payout	-	Rel Volume	1.34	Prev Close	50.78
Sales Surprise	4.03%	EPS Surprise	319.93%	Sales Q/Q	24.95%	Earnings	May 07 BMO	Avg Volume	127.83K	Price	53.09
SMA20	28.57%	SMA50	42.21%	SMA200	227.65%	Trades		Volume	170,926	Change	4.55%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Initiated	JMP Securities	Mkt Outperform	$70
Apr-23-24	Upgrade	Barrington Research	Mkt Perform → Outperform	$45
Mar-15-24	Initiated	Barrington Research	Mkt Perform
Apr-25-22	Initiated	Jefferies	Hold	$5

May-08-24 04:05PM	Dave to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
May-07-24 07:30AM	Dave Reports Record First Quarter 2024 Results (GlobeNewswire) +12.38%
Apr-19-24 08:30AM	Dave to Report First Quarter 2024 Results on May 7, 2024 at 8:30 a.m. ET (GlobeNewswire)
Apr-18-24 04:39PM	Socure Releases Multi-Layered AI Defense System That Defeats Deepfakes and Other Identity Fraud in Under Two Seconds (PR Newswire)
Mar-21-24 08:30AM	Dave to Participate in the FT Partners Equity Research Weekly Forum on March 22nd (GlobeNewswire) +5.60%
08:17AM	Loading…
Mar-06-24 08:17AM	Dave Inc. (NASDAQ:DAVE) Q4 2023 Earnings Call Transcript (Insider Monkey) -12.17%
Mar-05-24 07:30AM	Dave Reports Record Fourth Quarter and Full Year 2023 Results; Reaches Significant Quarterly Profitability Milestone (GlobeNewswire) +64.38%
Feb-22-24 08:30AM	Dave to Participate in a Fireside Chat at the Citizens JMP Technology Conference on March 5 in San Francisco (GlobeNewswire)
Feb-20-24 04:05PM	Dave to Report Fourth Quarter and Full Year 2023 Results on March 5, 2024 at 8:30 a.m. ET (GlobeNewswire) -7.74%
Feb-14-24 08:30AM	Dave to Participate at the Wolfe Fintech Forum on March 14 (GlobeNewswire) +5.47%
Feb-13-24 09:00AM	Neobank Dave Joins the American Fintech Council to Create Financial Inclusivity in Digital Banking (PR Newswire)
Jan-30-24 09:00AM	Dave's Repurchase of FTX Convertible Note for $71 Million Finalized (PR Newswire)
Jan-16-24 09:00AM	Aisera & Dave Launch DaveGPT, a Generative AI Customer Service Assistant to Enable Personalized On-Demand Support (PR Newswire)
Jan-05-24 09:00AM	Dave Announces Repurchase of $100 million Convertible Note from FTX for $71 million (PR Newswire)
Nov-12-23 08:59AM	Dave Inc. (NASDAQ:DAVE) Q3 2023 Earnings Call Transcript (Insider Monkey)
04:05PM	Loading…
Nov-07-23 04:05PM	Dave Announces Third Quarter 2023 Results (GlobeNewswire)
Oct-24-23 08:30AM	Dave to Report Third Quarter 2023 Results on November 7, 2023 at 4:30 p.m. ET (GlobeNewswire)
Sep-18-23 04:05PM	Dave Amends Credit Facility to Increase Capacity and Advance Rate, Reduce Cost of Funds, and Extend Maturity (GlobeNewswire)
Sep-07-23 04:30PM	Dave Announces John Ricci's Retirement, Names Joan Aristei as Successor and Chief Legal Officer (PR Newswire) -6.78%
Aug-23-23 08:30AM	Dave to Participate at the H.C. Wainwright Global Investment Conference on September 12 (GlobeNewswire)
Aug-08-23 04:15PM	Entities Managed by Imran Khan to Acquire 2.5% Stake in Dave via Secondary Market Transaction (PR Newswire)
04:05PM	Dave Announces Second Quarter 2023 Results (GlobeNewswire)
Aug-02-23 10:19AM	Investors in Dave (NASDAQ:DAVE) from a year ago are still down 69%, even after 19% gain this past week (Simply Wall St.)
Aug-01-23 09:00AM	Dave Announces 4.00% Annual Percentage Yield For Checking and Savings Accounts (PR Newswire)
Jul-27-23 12:00PM	Dave Partners with Drew League, LA's Pro-Am Basketball Team (PR Newswire)
Jul-20-23 08:30AM	Dave to Report Second Quarter 2023 Results on August 8, 2023 at 4:30 p.m. ET (GlobeNewswire)
Jul-10-23 04:49PM	Dave Inc. Announces Appointment of Yadin Rozov to Board of Directors (PR Newswire)
May-31-23 04:05PM	Dave to Present at the LD Micro Invitational XIII on June 7, 2023 (Newsfile)
May-23-23 09:00AM	Dave Members Earn More Than $1 Million with New Survey Offering (PR Newswire) +14.06%
May-13-23 08:06AM	US$5.50: That's What Analysts Think Dave Inc. (NASDAQ:DAVE) Is Worth After Its Latest Results (Simply Wall St.)
04:05PM	Loading…
May-09-23 04:05PM	Dave Announces First Quarter 2023 Results (GlobeNewswire) -6.41%
Apr-27-23 12:30PM	Dave Schedules First Quarter 2023 Conference Call for May 9, 2023 at 4:30 p.m. ET (GlobeNewswire)
Mar-20-23 02:00PM	Sidoti's Small-Cap Virtual March Conference (ACCESSWIRE)
Mar-06-23 04:05PM	Dave Inc. Announces Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-02-23 03:30PM	Dave to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-22-23 08:30AM	Dave Inc. Schedules Fourth Quarter and Full Year 2022 Conference Call for March 6, 2023 at 5:00 p.m. ET (GlobeNewswire)
Feb-14-23 09:30AM	Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences (ACCESSWIRE)
Jan-05-23 05:10PM	Dave Inc. Announces Reverse Stock Split Effective (Business Wire)
Dec-27-22 05:54AM	Dave Inc.'s (NASDAQ:DAVE) market cap up US$13m last week, benefiting both individual investors who own 38% as well as insiders (Simply Wall St.) -9.02%
Dec-14-22 12:38PM	This Christmas, Consider a Festive Rack of Ribs (Bloomberg)
Nov-17-22 01:08PM	10 Best Stocks Under $20 (Insider Monkey) -10.95%
Nov-12-22 08:44AM	Recent gains in Dave Inc. (NASDAQ:DAVE) help add back some value on insider purchases worth US$15m, still down US$15m (Simply Wall St.)
Nov-11-22 08:30AM	Dave to Participate in Upcoming Investor Conferences (GlobeNewswire) +14.67%
Nov-10-22 04:42PM	Dave Reports Third Quarter 2022 Financial Results (GlobeNewswire) +5.89%
Nov-02-22 08:30AM	Dave Reaches Significant Corporate Milestone - Over $5 Billion in Overdraft Advances Since the Company's Founding (PR Newswire) -12.72%
Oct-31-22 04:27PM	Dave to Announce Third Quarter 2022 Results on November 10, 2022 (GlobeNewswire)
Sep-06-22 08:30AM	Dave Announces the Appointment of Chien-Liang Chou as its New Chief Technology Officer (PR Newswire)
Sep-02-22 07:03AM	Owning a franchise can mean big business. Here's how big some Minnesota franchises can be. (American City Business Journals) -5.32%
Aug-25-22 08:30AM	Dave Appoints Brand Marketing and Digital Product Expert Tesa Aragones to Board of Directors (PR Newswire)
Aug-23-22 10:56AM	Tahoe Joe's closes Roseville restaurant (American City Business Journals)
Aug-15-22 10:15AM	Dave Founder & CEO Jason Wilk to Host Public.com Town Hall for Retail Investors (GlobeNewswire) -11.56%
Aug-11-22 04:28PM	Dave Reports Second Quarter 2022 Results (GlobeNewswire) +15.37%
Aug-10-22 10:00AM	Earnings Preview: Brinker International (EAT) Q4 Earnings Expected to Decline (Zacks) +6.34%
Aug-08-22 10:00AM	Analysts Estimate BBQ Holdings (BBQ) to Report a Decline in Earnings: What to Look Out for (Zacks) -8.33%
Jul-26-22 06:00PM	BBQ Holdings (BBQ) Gains As Market Dips: What You Should Know (Zacks) +7.43%
Jul-21-22 08:30AM	Dave to Announce Second Quarter 2022 Results on August 11, 2022 (GlobeNewswire)
06:00AM	Why one strategist calls this market rally 'socially acceptable volatility': Morning Brief (Yahoo Finance)
Jul-19-22 06:00PM	BBQ Holdings (BBQ) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-14-22 06:16PM	BBQ Holdings (BBQ) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-12-22 09:16AM	Do Insiders Own Lots Of Shares In Dave Inc. (NASDAQ:DAVE)? (Simply Wall St.) -5.96%
09:15AM	Americans Cancel Summer Vacations (Business Wire)
Jul-11-22 10:38AM	Here's Why Investors Should Retain Dave & Buster's (PLAY) Stock (Zacks) -7.00%
Jul-08-22 11:16AM	Impressive Comps Growth Aid Chipotle (CMG), Inflation Hurts (Zacks) -5.25%
11:14AM	Restaurant Brands (QSR) Banks on Expansion Efforts, Traffic Low (Zacks)
09:40AM	Is Arcos Dorados (ARCO) a Great Value Stock Right Now? (Zacks)
Jul-06-22 12:50PM	Yum! Brands (YUM) Pizza Hut Partners to Open Stores in Saudi (Zacks)
10:43AM	Yum! Brands (YUM) Plans to Sell KFC Restaurants in Russia (Zacks)
Jul-05-22 12:50PM	Here's Why Investors Should Retain Yum China (YUMC) Stock (Zacks)
Jul-01-22 08:10AM	Why to Invest in Builders FirstSource (BLDR) Amid Supply Woes (Zacks)
Jun-29-22 06:15PM	BBQ Holdings (BBQ) Dips More Than Broader Markets: What You Should Know (Zacks) -8.34%
12:16PM	Here's Why You Should Retain Wendy's (WEN) in Your Portfolio (Zacks)
11:40AM	BBQ vs. YUMC: Which Stock Should Value Investors Buy Now? (Zacks)
11:07AM	Here's Why Investors Should Retain Domino's (DPZ) Stock Now (Zacks)
Jun-28-22 12:21PM	Brinker (EAT) Expands Brands Presence With Grubhub Partnership (Zacks)
Jun-27-22 12:13PM	Here's Why You Should Retain Papa John's (PZZA) Stock Now (Zacks) -6.69%
10:29AM	BJ's Restaurants (BJRI) Soars 6.4%: Is Further Upside Left in the Stock? (Zacks)
10:21AM	Darden (DRI) Down 21% YTD: More Pain or Relief Ahead? (Zacks)
Jun-24-22 08:55AM	Here's Why Investors Should Steer Clear of Cracker Barrel (CBRL) (Zacks) +5.65%
Jun-23-22 06:00PM	BBQ Holdings (BBQ) Stock Sinks As Market Gains: What You Should Know (Zacks)
11:22AM	Darden (DRI) Q4 Earnings & Revenue Top Estimates, Rise Y/Y (Zacks)
11:07AM	GMS Q4 Earnings & Revenues Top Estimates, Margins Improve Y/Y (Zacks)
Jun-22-22 09:31AM	Here's Why Investor Should Retain Jack in the Box (JACK) Stock (Zacks) -8.61%
Jun-21-22 06:15PM	BBQ Holdings (BBQ) Gains But Lags Market: What You Should Know (Zacks)
08:49AM	Why to Invest in Beacon's (BECN) Stock Amid Supply Woes (Zacks)
Jun-20-22 04:50AM	The Zacks Analyst Blog Highlights Arcos Dorados, BBQ Holdings, The ONE Group and Potbelly (Zacks)
Jun-17-22 12:26PM	Chipotle (CMG) Spruces Up Menu With Mexican Cauliflower Rice (Zacks)
08:17AM	4 Stocks to Buy on Steady Growth in Restaurant Sales (Zacks)
07:57AM	4 Restaurant Stocks to Buy on Strong Sales (Zacks)
Jun-16-22 02:03PM	Dave Increases ExtraCash Overdraft Limit to $500 And Launches Instant Access (PR Newswire)
11:20AM	Here's Why You Should Retain YUM! Brands (YUM) Stock Now (Zacks)
Jun-15-22 10:19AM	Chipotle (CMG) Boosts Digital Space With Loyalty Program Launch (Zacks) +7.03%
Jun-14-22 10:51AM	Here's Why You Should Retain BJ's Restaurants (BJRI) Stock Now (Zacks)
Jun-13-22 11:40AM	BBQ or YUMC: Which Is the Better Value Stock Right Now? (Zacks)
11:12AM	Here's Why You Should Retain Red Robin (RRGB) Stock Now (Zacks)
08:28AM	Enterprise Products Partners and Target have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Jun-10-22 10:46AM	Starbucks (SBUX) Down 32% in Past 6 Months: Is Revival Likely? (Zacks) -20.80%
09:40AM	Are Investors Undervaluing BBQ Holdings (BBQ) Right Now? (Zacks)
Jun-09-22 08:16AM	Fastenal's (FAST) Average Daily Sales Increase 17.6% in May (Zacks) -11.35%
Jun-08-22 11:31AM	Cracker Barrel (CBRL) Beats Q3 Earnings Estimates, Stock Down (Zacks)
11:15AM	Dave & Buster's (PLAY) Q1 Earnings Top Estimates, Stock Up (Zacks)

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Section 32 Fund 1, LP	10% Owner	May 07 '24	Sale	48.90	450,000	22,005,000	2,138,232	May 09 04:01 PM
Beilman Kyle	CFO and Secretary	Mar 14 '24	Sale	33.26	4,188	139,293	189,143	Mar 15 08:52 PM
Wilk Jason	Chief Executive Officer	Mar 14 '24	Sale	33.26	2,400	79,824	106,370	Mar 15 08:43 PM
Rozov Yadin	Director	Mar 07 '24	Buy	37.31	800	29,848	96,452	Mar 11 05:03 PM
Preston Dan	Director	Mar 05 '24	Option Exercise	0.96	12,000	11,520	45,039	Mar 07 05:13 PM
Preston Dan	Director	Mar 05 '24	Sale	32.02	12,000	384,240	33,039	Mar 07 05:13 PM
Rozov Yadin	Director	Dec 04 '23	Buy	6.40	12,941	82,760	95,652	Dec 06 07:35 PM
Beilman Kyle	CFO and Secretary	Sep 07 '23	Sale	6.27	2,350	14,741	193,331	Sep 11 09:29 PM
Wilk Jason	Chief Executive Officer	Sep 07 '23	Sale	6.53	1,263	8,247	108,770	Sep 11 09:47 PM
Section 32 Fund 1, LP	10% Owner	Aug 08 '23	Sale	5.73	297,771	1,707,657	2,588,232	Aug 10 04:30 PM
Beilman Kyle	CFO and Secretary	Jun 02 '23	Sale	5.29	1,988	10,521	195,681	Jun 06 08:38 PM
Wilk Jason	Chief Executive Officer	Jun 02 '23	Sale	5.29	1,112	5,887	110,033	Jun 06 08:39 PM

Open in Screener

ORMP

Oramed Pharmaceuticals, Inc

May 09 • 04:00PM ET

2.38

Dollar change -0.05
Percentage change -2.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ORMP Oramed Pharmaceuticals, Inc daily Stock Chart

Held by: IWC AVSC DFAS DFAT AVUS DFUS DCOR GWX SPDW

Index	-	P/E	17.49	EPS (ttm)	0.14	Insider Own	14.35%	Shs Outstand	40.34M	Perf Week	1.71%
Market Cap	96.44M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	34.70M	Perf Month	-10.53%
Income	5.52M	PEG	-	EPS next Q	-	Inst Own	13.12%	Short Float	1.06%	Perf Quarter	-11.52%
Sales	1.34M	P/S	71.97	EPS this Y	-	Inst Trans	-39.92%	Short Ratio	2.52	Perf Half Y	14.42%
Book/sh	4.06	P/B	0.59	EPS next Y	-	ROA	2.89%	Short Interest	0.37M	Perf Year	-18.77%
Cash/sh	4.00	P/C	0.60	EPS next 5Y	-	ROE	3.50%	52W Range	1.67 - 5.25	Perf YTD	3.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	3.37%	52W High	-54.67%	Beta	1.82
Dividend TTM	-	Quick Ratio	3.06	Sales past 5Y	-50.43%	Gross Margin	85.37%	52W Low	42.51%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	3.06	EPS Y/Y TTM	114.55%	Oper. Margin	-1176.79%	RSI (14)	44.68	Volatility	4.74% 5.77%
Employees	15	Debt/Eq	0.32	Sales Y/Y TTM	-50.43%	Profit Margin	412.31%	Recom	3.00	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	252.63%	Payout	0.00%	Rel Volume	0.32	Prev Close	2.43
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	146.02K	Price	2.38
SMA20	-0.07%	SMA50	-11.46%	SMA200	-8.93%	Trades		Volume	46,422	Change	-2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold	$30 → $3
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight	$20
Apr-20-21	Initiated	Canaccord Genuity	Buy	$27
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy	$11
Mar-11-20	Initiated	Aegis Capital	Buy	$5.50
Sep-11-19	Initiated	Ladenburg Thalmann	Buy	$7
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy	$20
May-26-16	Reiterated	FBR Capital	Outperform	$15 → $20
Dec-01-15	Reiterated	H.C. Wainwright	Buy	$24 → $25
Nov-19-15	Initiated	FBR Capital	Outperform	$15
Apr-13-15	Resumed	MLV & Co	Buy	$27 → $30
Jan-30-14	Reiterated	Aegis Capital	Buy	$30 → $35
Jan-08-14	Reiterated	Aegis Capital	Buy	$25 → $30
Jan-08-14	Initiated	MLV & Co	Buy	$27
Dec-03-13	Initiated	Aegis Capital	Buy	$25

Show Previous Ratings

Today 06:51PM	Oramed: Q1 Earnings Snapshot (Associated Press Finance)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-07-24 10:53AM	ORMP Stock Earnings: Oramed Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Feb-20-24 08:30AM	Oramed Letter to Shareholders (PR Newswire)
Nov-10-23 05:03AM	Oramed: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Loading…
Oct-24-23 08:30AM	PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization (PR Newswire)
Oct-05-23 10:13AM	ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801 (Zacks)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire)
Sep-21-23 06:11PM	Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company (PR Newswire)
04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -5.56%
Aug-02-23 07:45AM	Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally (PR Newswire)
Jun-20-23 07:55AM	Oramed to Present at the 83rd American Diabetes Association Conference (PR Newswire)
Jun-17-23 09:54AM	Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-30-23 11:06AM	ORMP: Advancing Development Efforts in China (Zacks Small Cap Research)
07:55AM	Loading…
May-18-23 07:55AM	Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit (PR Newswire) +13.22%
May-15-23 09:05AM	Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China (PR Newswire) +10.60%
May-12-23 01:03PM	Oramed: Q1 Earnings Snapshot (AP Finance)
May-02-23 10:51AM	Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company (Bloomberg) +6.53%
May-01-23 04:45PM	Oramed Appoints Ben Shapiro to its Board of Directors (PR Newswire) +7.93%
Mar-27-23 06:57AM	The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable (Simply Wall St.)
Feb-09-23 07:55AM	Oramed Pharmaceuticals Issues Shareholder Update (PR Newswire) +5.77%
Jan-25-23 08:05AM	ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts (Zacks Small Cap Research)
Jan-12-23 12:30PM	Oramed Pharmaceuticals Stock Plummets After Insulin Test Results (The Wall Street Journal) -76.46%
11:50AM	Why Oramed Pharmaceuticals Stock Is Crashing Today (Motley Fool)
08:02AM	Orameds oral insulin pill fails; stock is down 72% (MarketWatch)
06:19AM	Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study (Benzinga)
Jan-11-23 08:00PM	Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes (PR Newswire) +5.78%
Jan-08-23 07:38AM	Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation (Simply Wall St.)
Jan-04-23 07:55AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire)
08:25AM	Loading…
Dec-21-22 08:25AM	Oramed Letter to Shareholders (PR Newswire) +14.25%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 08:40AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire)
Nov-21-22 10:45AM	ORMP: Data from NASH Phase 2 Study Positive Takeaways (Zacks Small Cap Research)
Nov-17-22 01:12PM	Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study (Benzinga)
12:25PM	Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire)
Nov-16-22 05:06AM	Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -8.56%
Nov-14-22 07:55AM	Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea (PR Newswire)
Nov-10-22 04:30PM	Oramed Reports Third Quarter 2022 Financial Results (PR Newswire) +5.96%
Nov-09-22 08:40AM	Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH (PR Newswire) -6.19%
Oct-17-22 08:07AM	Oramed Pharmaceuticals (NASDAQ:ORMP) shareholders have earned a 27% CAGR over the last three years (Simply Wall St.) +7.69%
Oct-07-22 11:06AM	Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study (Benzinga) -7.19%
08:40AM	Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine (PR Newswire)
Sep-13-22 11:59AM	Oramed Oral Insulin Shows Evidence For NASH Treatment (Benzinga)
08:40AM	Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate (PR Newswire)
Sep-06-22 07:55AM	Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire) -12.36%
Aug-25-22 09:15AM	ORMP: Upcoming data from ORA-D-013-1 & NASH studies could be catalysts (Zacks Small Cap Research)
Aug-01-22 07:40AM	We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-26-22 07:55AM	Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial (PR Newswire)
Jul-12-22 02:22PM	Why Oramed Pharmaceuticals Stock Is On Fire Today (Motley Fool)
Jul-11-22 07:55AM	Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference (PR Newswire) +5.61%
Jul-08-22 05:56PM	Why Oramed Pharmaceuticals Stock Rocketed Higher Today (Motley Fool) +44.37%
Jul-07-22 07:55AM	Oramed Letter to Shareholders (PR Newswire) +12.70%
Jun-01-22 07:55AM	Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board (PR Newswire) -5.40%
May-24-22 08:10AM	Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes (PR Newswire) -5.23%
May-18-22 07:55AM	Oramed to Present at H.C. Wainwright Global Investment Conference (PR Newswire) -13.42%
May-10-22 07:12AM	Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week (Simply Wall St.) -6.12%
May-03-22 08:10AM	Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 (PR Newswire)
Apr-27-22 08:10AM	ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing (Zacks Small Cap Research)
Apr-05-22 08:25AM	Oramed Granted NASH Patent in Europe (PR Newswire)
Apr-04-22 08:25AM	Oramed Appoints Yadin Rozov to its Board of Directors (PR Newswire)
Mar-29-22 08:25AM	Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians (PR Newswire)
Mar-22-22 08:25AM	Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes (PR Newswire)
Mar-16-22 08:25AM	Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial (PR Newswire) +6.88%
Mar-10-22 08:25AM	Oramed to Present at Barclays Global Healthcare Conference (PR Newswire)
Feb-23-22 11:25AM	ORMP: Moving Multiple Candidates & Studies Forward (Zacks Small Cap Research) -6.11%
Feb-22-22 05:38AM	We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate (Simply Wall St.)
Jan-12-22 08:45AM	Oramed Issues Annual Message to Shareholders (PR Newswire)
Jan-05-22 07:30AM	Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins (PR Newswire) -8.29%
Dec-29-21 06:14AM	Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh (MarketWatch)
06:00AM	Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia (PR Newswire)
06:00AM	Israel's Oramed gets Vietnam pre-order for 10 mln COVID-19 vaccine doses (Reuters)
Dec-14-21 08:00AM	Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa (PR Newswire) -6.76%
Dec-08-21 07:30AM	Oramed Pharmaceuticals Appoints Chief Legal Officer (PR Newswire)
Nov-24-21 08:40AM	Oramed to Join MSCI USA Small Cap Index (PR Newswire)
Nov-23-21 08:25AM	Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study (PR Newswire)
Nov-18-21 07:40AM	Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (PR Newswire)
Nov-11-21 09:25AM	Oramed to Present at H.C. Wainwright 7th Annual Israel Conference (PR Newswire)
Nov-10-21 10:19AM	ORMP: Financing Enhances Flexibility to Advance Multiple Opportunities (Zacks Small Cap Research) -6.30%
Nov-08-21 08:10AM	Oramed Announces Closing of $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) +10.88%
Nov-03-21 11:59AM	Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (PR Newswire) -12.89%
Oct-29-21 07:25AM	Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial (PR Newswire)
Sep-23-21 08:25AM	Oramed to Present at Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire) +8.94%
Sep-15-21 08:10AM	Oramed's Phase 2 Oral Insulin NASH Trial Reaches Over 50% Enrollment (PR Newswire)
Sep-09-21 08:25AM	Oramed to Present at H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-26-21 07:05AM	ORMP: Multiple Opportunities Advance; Senior Team Expands to Support Growth (Zacks Small Cap Research)
Aug-24-21 08:25AM	Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials (PR Newswire)
06:26AM	Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Will Probably Have Their Compensation Approved By Shareholders (Simply Wall St.)
Aug-16-21 08:25AM	Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism (PR Newswire) -13.97%
Aug-09-21 08:40AM	Oramed to Present at Canaccord Genuity's 41st Annual Growth Conference (PR Newswire) +15.50%
Aug-05-21 06:40AM	Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021 (PR Newswire) +14.70%
Jul-29-21 08:25AM	Oramed Pharmaceuticals Appoints Chief Commercial Officer (PR Newswire) +5.58%
Jul-21-21 11:44AM	Oramed Will Soon Start Clinical Trials For Oral COVID-19 Vaccine In Israel, Out licensed Injectable Version To Premas Biotech In India (Benzinga) +9.66%
08:25AM	Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial (PR Newswire)
Jul-19-21 07:18AM	We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate (Simply Wall St.)
Jun-22-21 11:22AM	ORMP: Inclusion in Russell Indices Expands Pool of Potential ORMP Investors (Zacks Small Cap Research)
08:40AM	Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes (PR Newswire)
Jun-18-21 12:52PM	Oramed Pharmaceuticals Inc. (ORMP) Fell Out Of Favor With Hedge Funds (Insider Monkey)
Jun-08-21 08:10AM	Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study (PR Newswire)
May-25-21 08:40AM	Oramed Issues Letter to Shareholders with Updates on Oral Insulin and COVID-19 Vaccine (PR Newswire)

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CORZ

Core Scientific Inc

DAVE

Dave Inc

ORMP

Oramed Pharmaceuticals, Inc

Upgrade your FINVIZ experience